報價延遲最少15分鐘:2026/03/30 10:52 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.295 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.95/0.05
|
|
企業價值
601.85M
|
| 資產負債 |
|
每股賬面淨值
3.94
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
824.50M
|
|
每股收益
7.88
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US. |
